Serum zonulin levels are increased in Alzheimer's disease but not in vascular dementia.
Aging
Alzheimer’s disease
Blood–brain barrier
Dementia
Gut-brain-microbiota axis
Permeability
Journal
Aging clinical and experimental research
ISSN: 1720-8319
Titre abrégé: Aging Clin Exp Res
Pays: Germany
ID NLM: 101132995
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
16
02
2023
accepted:
02
06
2023
medline:
28
8
2023
pubmed:
20
6
2023
entrez:
19
6
2023
Statut:
ppublish
Résumé
Zonulin is involved in the integrity and functioning of both intestinal-epithelial barrier and blood-brain barrier (BBB) by regulating tight junction molecular assembly. Since changes in microbiota and BBB may play a role in neurodegenerative disorders, we aimed to determine whether serum zonulin levels change in older patients affected by different types of dementia or mild cognitive impairment (MCI). We evaluated serum zonulin levels in patients with late-onset AD (LOAD), vascular dementia (VAD), MIXED (AD + VAD) dementia, amnestic MCI, and in healthy controls. Compared with controls, serum zonulin increased in LOAD, MIXED dementia, and aMCI but not in VAD, independent of potential confounders (ANCOVA p = 0.01; LOAD vs controls, p = 0.01; MIXED vs. controls, p = 0.003; aMCI vs. controls, p = 0.04). Notably, aMCI converting to dementia showed significantly higher levels of zonulin compared with stable aMCI (p = 0.04). Serum zonulin inversely correlated with the standardized Mini-Mental State Examination (MMSE) score (p < 0.05), regardless of potential confounders. We found increased serum zonulin levels in patients with aMCI, LOAD and MIXED dementia, but not in VAD; moreover, zonulin levels were higher in aMCI converting to AD compared with stable ones. Our findings suggest that a dysregulation of intestinal-epithelial barrier and/or BBB may be an early specific event in AD-related neurodegeneration.
Sections du résumé
BACKGROUND
BACKGROUND
Zonulin is involved in the integrity and functioning of both intestinal-epithelial barrier and blood-brain barrier (BBB) by regulating tight junction molecular assembly.
AIM
OBJECTIVE
Since changes in microbiota and BBB may play a role in neurodegenerative disorders, we aimed to determine whether serum zonulin levels change in older patients affected by different types of dementia or mild cognitive impairment (MCI).
METHODS
METHODS
We evaluated serum zonulin levels in patients with late-onset AD (LOAD), vascular dementia (VAD), MIXED (AD + VAD) dementia, amnestic MCI, and in healthy controls.
RESULTS
RESULTS
Compared with controls, serum zonulin increased in LOAD, MIXED dementia, and aMCI but not in VAD, independent of potential confounders (ANCOVA p = 0.01; LOAD vs controls, p = 0.01; MIXED vs. controls, p = 0.003; aMCI vs. controls, p = 0.04). Notably, aMCI converting to dementia showed significantly higher levels of zonulin compared with stable aMCI (p = 0.04). Serum zonulin inversely correlated with the standardized Mini-Mental State Examination (MMSE) score (p < 0.05), regardless of potential confounders.
DISCUSSION
CONCLUSIONS
We found increased serum zonulin levels in patients with aMCI, LOAD and MIXED dementia, but not in VAD; moreover, zonulin levels were higher in aMCI converting to AD compared with stable ones.
CONCLUSIONS
CONCLUSIONS
Our findings suggest that a dysregulation of intestinal-epithelial barrier and/or BBB may be an early specific event in AD-related neurodegeneration.
Identifiants
pubmed: 37337075
doi: 10.1007/s40520-023-02463-2
pii: 10.1007/s40520-023-02463-2
pmc: PMC10460299
doi:
Substances chimiques
zonulin
0
Haptoglobins
0
Protein Precursors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1835-1843Informations de copyright
© 2023. The Author(s).
Références
Transl Oncol. 2009 Aug 18;2(3):117-20
pubmed: 19701495
Gerontologist. 1969 Autumn;9(3):179-86
pubmed: 5349366
J Neurol Sci. 1982 Jan;53(1):9-22
pubmed: 7057204
PLoS One. 2013 Apr 05;8(4):e60655
pubmed: 23637756
Antioxid Redox Signal. 2020 Jul 20;33(3):191-210
pubmed: 32143546
Physiol Rev. 2011 Jan;91(1):151-75
pubmed: 21248165
Proc Natl Acad Sci U S A. 1991 Jun 15;88(12):5242-6
pubmed: 2052603
Cell Mol Life Sci. 2017 Jun;74(12):2167-2201
pubmed: 28197669
J Cell Sci. 2000 Dec;113 Pt 24:4435-40
pubmed: 11082037
Clin Geriatr Med. 2013 Nov;29(4):753-72
pubmed: 24094295
Geroscience. 2018 Feb;40(1):61-69
pubmed: 29428983
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
J Alzheimers Dis. 2018;63(4):1223-1234
pubmed: 29782323
J Clin Invest. 1995 Aug;96(2):710-20
pubmed: 7635964
JAMA. 1963 Sep 21;185:914-9
pubmed: 14044222
Immunity. 2009 Nov 20;31(5):722-35
pubmed: 19836264
Aging Clin Exp Res. 2021 Jul;33(7):1895-1902
pubmed: 32918697
Mult Scler. 2003 Dec;9(6):540-9
pubmed: 14664465
Brain. 1966 Dec;89(4):663-82
pubmed: 4163579
F1000Res. 2020 Jan 31;9:
pubmed: 32051759
Front Cell Infect Microbiol. 2021 Mar 17;11:625913
pubmed: 33816335
Front Aging Neurosci. 2021 May 28;13:650047
pubmed: 34122039
Neurology. 1993 Feb;43(2):250-60
pubmed: 8094895
Neurobiol Aging. 2017 Jan;49:60-68
pubmed: 27776263
J Neurogastroenterol Motil. 2019 Jan 31;25(1):48-60
pubmed: 30646475
Acta Neurol Scand. 2020 Mar;141(3):250-255
pubmed: 31715011
J Am Med Dir Assoc. 2017 Sep 1;18(9):810.e1-810.e4
pubmed: 28676292
Geroscience. 2020 Feb;42(1):159-167
pubmed: 31745860
FASEB J. 2011 Jan;25(1):144-58
pubmed: 20852064
Int Psychogeriatr. 1997;9 Suppl 1:87-94; discussion 143-50
pubmed: 9447431
Cold Spring Harb Perspect Biol. 2018 Jan 2;10(1):
pubmed: 28507021
Acta Psychiatr Scand. 2009 Apr;119(4):252-65
pubmed: 19236314
CNS Spectr. 2008 Jan;13(1):45-53
pubmed: 18204414
Clin Gastroenterol Hepatol. 2012 Oct;10(10):1096-100
pubmed: 22902773
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16799-804
pubmed: 19805376
Tissue Barriers. 2016 Oct 21;4(4):e1251384
pubmed: 28123927
Mini Rev Med Chem. 2023;23(3):307-319
pubmed: 35733303
Biochem Biophys Res Commun. 2018 Dec 9;507(1-4):274-279
pubmed: 30449598